Skip to main content
. 2015 Dec 2;18(7Suppl 6):20271. doi: 10.7448/IAS.18.7.20271

Table 1.

ARVs available for term infants in first four weeks of life and for preterm newborn infants

Term Preterm Comments
Reverse transcriptase inhibitors
Zidovudine X X IV formulation available
Lamivudine X Dosage available for first month
Emtricitabine X Dosage from 0 to 3 months
Stavudine X
Non-nucleoside reverse transcriptase inhibitors
Nevirapine X X Dosages available for prevention only
Protease inhibitors
Lopinavir-ritonavir X (Recommended only after 2 weeks of age and 42 weeks post-conception) If used earlier than 42 weeks post-conception age, therapeutic drug monitoring and clinical and cardiac monitoring recommended

From Ref. [11].